About this trial
This prospective randomized controlled trial aims to compare the analgesic efficacy of three non-opioid analgesics (ibuprofen, paracetamol, and tenoxicam) during extracorporeal shock wave lithotripsy (ESWL). All patients undergoing ESWL will be randomly assigned into four groups including a placebo group.
Pain intensity will be assessed using the Visual Analog Scale (VAS) at the 5th, 10th, 15th, and 20th minutes during the procedure. In addition to comparing analgesic efficacy, the study will evaluate patient-related and stone-related factors affecting pain perception, including body mass index, subcutaneous fat thickness, and stone density measured by Hounsfield Units.
The study also aims to assess the relationship between analgesic efficacy, energy levels applied during ESWL, and treatment outcomes such as stone-free rates. The findings may contribute to optimizing individualized pain management strategies and improving treatment efficiency in ESWL procedures.
Eligibility criteria
Qualifiers
Adult patients (≥18 years) undergoing ESWL for urinary stone disease
Patients with kidney or ureteral stones indicated for ESWL
Ability to provide informed consent
Disqualifiers
Known hypersensitivity or contraindication to ibuprofen, paracetamol, or tenoxicam
Chronic pain conditions or regular use of analgesics
Pregnancy or breastfeeding
Severe renal or hepatic impairment
Trial design
Treatments tested in this trial
- Ibuprofen (Brufen®)
- Paracetamol (drug)
- Tenoxicam
- Placebo